Specialty pharmaceutical company Tris Pharma's generic pharmaceuticals business has launched Dextroamphetamine Sulfate Oral Solution to treat attention deficit disorder with hyperactivity (ADHD) and narcolepsy in the US.
Available through wholesalers and distributors, as well as directly to the trade, the generic equivalent of ProCentra will be manufactured at Tris' FDA-inspected facility in Monmouth Junction, New Jersey, US.
Tris Pharma president and CEO Ketan Mehta said, "Dextroamphetamine Sulfate Oral Solution continues Tris' track record of bringing first-ever generics to the marketplace, as it's our fourth first-to-market generic product and the first of many to be launched through our new generic pharmaceuticals business."
The product is distributed in accordance with FDA and US Drug Enforcement Administration (DEA) regulations governing the handling of CII controlled substances.
Tris generic pharmaceuticals business president Janet Penner said, "With 13 FDA-approved ANDA products and a robust pipeline of ANDA development projects, we look forward to launching many more difference-making specialty generics."
